Navigation Links
Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
Date:9/23/2010

DEERFIELD, Ill. and LONDON, Sept. 23 /PRNewswire/ -- Following today’s announcements by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for rosiglitazone in the U.S. and Europe, Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals Europe Limited (“Takeda”) underscore the company’s commitment to ACTOS® (pioglitazone HCl) and ACTOS-containing medications, and to the millions of people living with type 2 diabetes.

As this news may cause concern or confusion among people with type 2 diabetes, Takeda encourages those with questions to speak with their health care provider. Takeda has consistently emphasized the importance of physician education and patient safety in communications involving ACTOS, and has prioritized communicating the appropriate use of ACTOS in patients with type 2 diabetes.

ACTOS is an effective prescription medication used with diet and exercise to improve blood sugar (glucose) control in many adults with type 2 diabetes. Since its launch, more than 100 million ACTOS prescriptions have been written globally. ACTOS offers an established safety profile regarding the risk of cardiovascular (CV) events in people living with type 2 diabetes. Although drugs may be in the same class and have the same use, they also may have different effects due to their unique chemical structure.

Takeda remains confident in the breadth, depth and consistency of ACTOS data. Controlled clinical studies, conducted over the past 11 years in more than 20,000 patients globally, show no evidence that ACTOS is associated with an increased risk of heart attack, stroke or death.

In 2005, Takeda was the first company to complete a rigorous, randomized, placebo-controlled study, the PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events) trial, assessing significant CV outcomes in people livi
'/>"/>

SOURCE Takeda Pharmaceutical North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
2. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
3. Takeda Responds to FDA Advisory Committee Recommendation
4. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
5. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
6. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
7. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
8. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
9. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
10. Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... MANCHESTER, England , July 22, 2014 ... AEX:PHIA) announced today that The Christie NHS Foundation Trust ... center, will join a consortium whose mission is to ... imaging (MRI) guided radiation therapy system. Such a system ... real-time visualization of cancer targets. "The ...
(Date:7/22/2014)... 22, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... and dosing of patients in its ongoing Phase 2 ... cancer under the revised clinical protocol agreed to with ... form of Halozyme,s proprietary recombinant human hyaluronidase under development ... "Our diligent effort to rapidly re-initiate ...
(Date:7/22/2014)... Fla. , July 22, 2014  Neurotrope Bioscience, ... signed a world-wide, exclusive license agreement with the Icahn ... ( Mount Sinai ) to utilize ... of Bryostatin-1 in the treatment of Niemann-Pick Type C ... are afflicted with Alzheimer-like symptoms. The license also covers ...
Breaking Medicine Technology:The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
... OKLAHOMA CITY, Jan. 6, 2011 Altheus Therapeutics, Inc., ... active-controlled Phase I clinical trial of the safety and ... left-sided, or distal, ulcerative colitis.  No serious adverse events ... excited to have achieved this milestone, as it prepares ...
... Calif., Jan. 6, 2011 Viveve, Inc. , ... it has received the European CE (Conformite Europeenne) mark ... non-surgical treatment of laxity of the vaginal introitus (opening), ... (Logo:   http://photos.prnewswire.com/prnh/20110106/SF25673LOGO ) "The CE mark ...
Cached Medicine Technology:Altheus Therapeutics Completes Phase I Clinical Study of Zoenasa™ in Ulcerative Colitis 2Viveve Obtains CE Mark for Gynecologic Treatment of Vaginal Laxity 2
(Date:7/22/2014)... the Clean Plate Club you eat pretty much everything ... A new Cornell University study shows that the average adult ... or her plate. "If you put it on ... Ph.D., author of the forthcoming book, Slim by Design, Professor ... Lab. , Wansink and co-author Katherine Abowd Johnson analyzed 1179 ...
(Date:7/22/2014)... Legislation backed by the drugstore lobby ... Act of 2014”) championing so-called “any willing pharmacy” ... availability of lower cost preferred pharmacy networks and ... next 10 years, according to new research from ... Management Association (PCMA). , The drugstore lobby targets ...
(Date:7/22/2014)... -- New guidelines on cholesterol treatment and cardiovascular risk ... risk of dying from atherosclerotic cardiovascular disease or of ... with a similar risk profile (based on age, smoking ... of this finding for when and how aggressively to ... Journal of Men,s Health , a peer-reviewed publication ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... (HealthDay News) -- One of the largest studies ever ... has uncovered 83 new sites on chromosomes that harbor ... by an international team of researchers, now bring the ... disorder to 108. Although these schizophrenia-associated genes ... to predict who will or will not develop the ...
Breaking Medicine News(10 mins):Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2
... brain cells suddenly went rogue and decided to become fat ... early in an organism,s development, cells make firm and more-or-less ... say, skin cells, brain cells or, well, fat cells. ... the possible candidates encoded in a cell,s genes, the cell ...
... SUNDAY, March 20 (HealthDay News) -- People with asthma may ... according to a new study that looked at the relationship ... which looked at medical records from the late 1960s through ... illness among asthmatics than other people. Researchers led by ...
... ill in Britain, according to new research published today by ... of almost 800 patients with severe mental illness such as ... or obese, and a disproportionate number suffered from diabetes, heart ... results of the two-year project in Kent are published today ...
... HealthDay Reporter , SATURDAY, March 19 (HealthDay News) -- ... quickly as experts previously have believed. In a study ... third outgrew it within 30 months. But that finding ... higher percentage of children outgrowing the allergy fairly quickly, said ...
... Today, during the 89th General Session & Exhibition of ... with the 40th Annual Meeting of the American Association ... the Canadian Association for Dental Research, lead researcher F. ... study titled "Biodegradable Tooth-binding Micelles Inhibit Streptococcus mutans ...
... 18, 2011)--The growing concern surrounding the release of ... in Japan has raised fears of radiation exposure ... plume of radioactivity crossing the Pacific Ocean. To ... American Association of Clinical Endocrinologists (AACE), the American ...
Cached Medicine News:Health News:Stanford researchers discover molecular determinant of cell identity 2Health News:Stanford researchers discover molecular determinant of cell identity 3Health News:Stanford researchers discover molecular determinant of cell identity 4Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 2Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 3Health News:Study Ties Asthma to Higher Odds for Diabetes, Heart Disease 4Health News:Life expectancy of severely mentally ill dramatically reduced due to poor physical health 2Health News:Outgrowing Milk Allergy May Take Some Babies Longer Than Expected 2Health News:Outgrowing Milk Allergy May Take Some Babies Longer Than Expected 3Health News:Biodegradable tooth-binding micelles inhibit Streptococcus mutans biofilm growth 2Health News:Radiation risks to health: A joint statement from leading scientific experts 2
... The Answer to Micro-Incision Cataract ... Technology With its unique double-step ... knife is ideal for MICS. ... reproducible incisions that allow you ...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Injection Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Medicine Products: